Targeting Unmet Disease Through Development of Best-in-Class Therapies
We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully design our product candidates, to be optimized, next-generation FXR agonists that we are initially developing as a differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate our FXR agonists as a potential first-in-class treatment for inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease and irritable bowel syndrome with diarrhea (IBS‑D). Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.